HK:9995 Stock Latest News
Company AnnouncementsRemeGen Issues Unaudited 2026 Third-Quarter Report and Cautions Investors3d ago
Company AnnouncementsRemeGen Sets Board Meeting to Approve Third-Quarter Results2w ago
Company AnnouncementsRemeGen Deploys Idle Funds Into RMB670 Million SPDB Wealth Products2w ago
Company AnnouncementsRemeGen Reshapes Company Secretariat and Hong Kong Representation Roles1M ago
Company AnnouncementsRemeGen Deploys Idle Funds Into Discloseable Wealth Management Products2M agoCompany AnnouncementsRemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones2M ago
Company AnnouncementsRemeGen Commits US$100 Million of Idle Funds to OCBC Wealth Products in Discloseable Transaction2M ago
Company AnnouncementsRemeGen Sets Board Meeting to Approve Interim 2026 Results2M ago
Company AnnouncementsRemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal2M ago
Company AnnouncementsRemeGen Deploys Idle Funds Into SPDB Wealth Products in Discloseable Transaction4M ago
Company AnnouncementsRemeGen Shareholders Back All Resolutions at 2025 AGM4M ago
Company AnnouncementsRemeGen Wins NMPA Approval for New Telitacicept Indication in Sjögren’s Disease4M ago
Company AnnouncementsRemeGen boosts cash management with new RMB300 million SPDB wealth product5M ago
Company AnnouncementsRemeGen Expands Use of Idle Funds in HTSC Wealth Products5M ago
Company AnnouncementsRemeGen Deploys Idle Funds Into HTSC Wealth Products in Discloseable Transaction5M ago
Company AnnouncementsRemeGen Sets 2025 AGM to Approve Reports, Capital Changes and New Board5M agoCompany AnnouncementsRemeGen Tightens Controls After Delay in Disclosing Wealth Management Deals5M ago